id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2001-E-0027-0023,FDA,FDA-2001-E-0027,U.S. Patent and Trademark Office to Wilmer Cutler Pickering Hale and Dorr LLP - Letter,Other,Letter(s),2012-06-05T04:00:00Z,2012,6,2012-06-05T04:00:00Z,,2012-06-05T12:42:13Z,,0,0,0900006481034550
FDA-2001-E-0027-0022,FDA,FDA-2001-E-0027,Letter to U. S. Patent and Trademark Office,Other,Letter(s),2012-04-03T04:00:00Z,2012,4,2012-04-03T04:00:00Z,,2024-03-13T18:08:18Z,,0,0,0900006480fe7a63
FDA-2001-E-0027-0021,FDA,FDA-2001-E-0027,FDA/CDER to United States Patent and Trademark Office - Letter,Other,Letter(s),2011-08-09T04:00:00Z,2011,8,2011-08-09T04:00:00Z,,2011-08-09T18:55:22Z,,0,0,0900006480edc64a
FDA-2001-E-0027-0020,FDA,FDA-2001-E-0027,Determinations of Regulatory Review Periods for Purposes of Patent Extensions: ANGIOMAX,Notice,N-Notice,2010-12-16T05:00:00Z,2010,12,2010-12-16T05:00:00Z,,2024-11-12T05:00:23Z,2010-31583,1,0,0900006480bb825a
FDA-2001-E-0027-0019,FDA,FDA-2001-E-0027,FDA/CDER to U.S. Patent and Trademark Office - Letter,Other,LET-Letter,2010-11-24T05:00:00Z,2010,11,2010-11-24T05:00:00Z,,2010-11-24T13:39:34Z,,0,0,0900006480ba28ee
FDA-2001-E-0027-0018,FDA,FDA-2001-E-0027,U.S. Patent & Trademark Office to Wilmer Cutler Pickering Hale and Dorr LLP - Letter,Other,LET-Letter,2010-09-14T04:00:00Z,2010,9,2010-09-14T04:00:00Z,,2013-07-27T23:30:50Z,,0,0,0900006480b4edf1
FDA-2001-E-0027-0017,FDA,FDA-2001-E-0027,US Patent and Trademark Office to Wilmer Cutler Pickering Hale and Dorr LLP - Denial of Application,Other,ADN-Denial of Application,2010-04-01T04:00:00Z,2010,4,,,2013-08-11T01:33:32Z,,0,0,0900006480acd82c
FDA-2001-E-0027-0016,FDA,FDA-2001-E-0027,"The Medicines Company v. USPTO, FDA, and DHHS, No. 1:10cv81-CMH/TCB, in the United States District Court for the Eastern District of Virginia (Alexandria Division), January 27, 2010 - Background Material",Supporting & Related Material,BKG-Background Material,2010-02-16T05:00:00Z,2010,2,,,2010-04-01T13:04:43Z,,0,0,0900006480aa5857
FDA-2001-E-0027-0015,FDA,FDA-2001-E-0027,"U.S. Patent & Trademark Office to The Medicine Company, November 20, 2001 re Notice of Final Determination  - Letter",Other,CP-Citizen Petition,2010-02-02T05:00:00Z,2010,2,,,2013-07-27T23:05:51Z,,0,0,0900006480a8ba8a
FDA-2001-E-0027-0012,FDA,FDA-2001-E-0027,U.S. Patent & Trademark Office to FDA/CDER - Letter,Other,LET-Letter,2010-02-01T05:00:00Z,2010,2,2010-02-01T05:00:00Z,,2013-08-11T03:06:37Z,,0,0,0900006480a88cb0
FDA-2001-E-0027-0011,FDA,FDA-2001-E-0027,The Medicines Company (Fish & Neave) - Application for Patent Extension Term,Other,APP-Application,2010-02-01T05:00:00Z,2010,2,2010-02-01T05:00:00Z,,2013-07-27T21:00:00Z,,0,0,09000064804b5c99
FDA-2001-E-0027-0014,FDA,FDA-2001-E-0027,"U.S. Patent & Trademark Office to The Medicine Company, March 2, 2002 re Corrected Notice of Final Determination - Letter",Other,LET-Letter,2010-02-01T05:00:00Z,2010,2,2010-02-01T05:00:00Z,,2013-07-27T23:05:43Z,,0,0,0900006480a88ef2
FDA-2001-E-0027-0013,FDA,FDA-2001-E-0027,"Blank Rome, LLP to FDA/CDER - Letter",Other,LET-Letter,2010-02-01T05:00:00Z,2010,2,2010-02-01T05:00:00Z,,2013-07-27T23:05:43Z,,0,0,0900006480a88cb3
FDA-2001-E-0027-0006,FDA,FDA-2001-E-0027,U.S. Patent & Trademark Office to FDA/CDER - Letter,Other,LET-Letter,2009-04-16T04:00:00Z,2009,4,2009-04-16T04:00:00Z,,2010-01-29T15:47:40Z,,0,0,09000064804b5cb1
FDA-2001-E-0027-0007,FDA,FDA-2001-E-0027,FDA/CDER to Dockets Management - Memorandum,Other,M-Memorandum,2009-04-16T04:00:00Z,2009,4,2009-04-16T04:00:00Z,,2010-01-29T15:50:37Z,,0,0,09000064804b5cb3
FDA-2001-E-0027-0010,FDA,FDA-2001-E-0027,"Generamedix Pharmaceuticals, Inc. - Citizen Petition",Other,CP-Citizen Petition,2009-04-16T04:00:00Z,2009,4,2009-04-16T04:00:00Z,,2009-04-16T22:01:01Z,,0,0,09000064804b5cbb
FDA-2001-E-0027-0008,FDA,FDA-2001-E-0027,"Envelope - [Generamedix Pharmaceuticals, Inc., (Blank Rome, LLP) - Citizen Petition]",Supporting & Related Material,CP-Citizen Petition (Supporting & Related Materials),2009-04-16T04:00:00Z,2009,4,,,2010-01-29T16:04:18Z,,0,0,09000064804b5cb8
FDA-2001-E-0027-0009,FDA,FDA-2001-E-0027,"Generamedix Pharmaceuticals, Inc., (Blank Rome, LLP) - Withdrawal",Other,WDL-Withdrawal,2009-04-16T04:00:00Z,2009,4,2009-04-16T04:00:00Z,,2013-07-27T21:00:00Z,,0,0,09000064804b5cc7
FDA-2001-E-0027-0005,FDA,FDA-2001-E-0027,FDA/CDER to the U.S. Patent and Trademark Office - Letter,Other,LET-Letter,2006-11-02T05:00:00Z,2006,11,,,2009-04-16T21:37:40Z,,0,0,09000064804b5cc2
FDA-2001-E-0027-0004,FDA,FDA-2001-E-0027,"Acknowledgement Letter to Generamedix Pharmaceuticals, Inc. - Correction",Other,CR-Correction,2006-10-23T04:00:00Z,2006,10,,,2010-01-29T15:42:31Z,,0,0,09000064804b5cc0
FDA-2001-E-0027-0002,FDA,FDA-2001-E-0027,"Acknowledgement Letter to Generamedix Pharmaceuticals, Inc.",Other,ACK-Acknowledgement Letter,2006-10-18T04:00:00Z,2006,10,,,2010-01-29T15:38:18Z,,0,0,09000064804b5cb6
FDA-2001-E-0027-0003,FDA,FDA-2001-E-0027,FDA-2001-E-0027-0002,Supporting & Related Material,ACK-Acknowledgement Letter (Supporting and Related Material),2006-10-18T04:00:00Z,2006,10,,,2010-01-29T15:36:58Z,,0,0,09000064804b5cbd
FDA-2001-E-0027-0001,FDA,FDA-2001-E-0027,FDA/CDER to the U. S. Patent & Trademark Office - Letter,Other,LET-Letter,2001-09-12T04:00:00Z,2001,9,,,2010-01-29T15:43:16Z,,0,0,09000064804b5c4f